Health Canada accepts nirsevimab regulatory submission for infant RSV
Yahoo! Finance USA,
Nirsevimab is the first investigational long-acting antibody designed for all infants to help protect against respiratory…
Nirsevimab is the first investigational long-acting antibody designed for all infants to help protect against respiratory…
Nirsevimab showed a 74.5% relative risk reduction against placebo in lower respiratory tract infections (LRTI) caused by…
Nirsevimab showed a 74.5% reduction in lower respiratory tract infections caused by RSV requiring medical care in healthy…
Nirsevimab showed a 74.5% reduction in lower respiratory tract infections caused by RSV requiring medical care in healthy…